Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia

British Journal of Clinical Pharmacology

Volumn 76, Issue 1, 2013, Pages 125-136

  Lennard, Lynne ^a   Cartwright, Cher Suzanne ^a   Wade, Rachel ^b   Richards, Susan M ^b   Vora, Ajay ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Childhood leukaemia; Genotype phenotype discordance; Mercaptopurine; Thioguanine; Thioguanine nucleotides; Thiopurine methyltransferase

Indexed keywords

DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; METHYLMERCAPTOPURINE NUCLEOTIDE; NUCLEOTIDE; PREDNISONE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE TITRATION; DRUG METABOLISM; ENZYME ACTIVITY; ERYTHROCYTE; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; METABOLITE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; VEIN OCCLUSION; WILD TYPE;

6-MERCAPTOPURINE; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; GREAT BRITAIN; GUANINE NUCLEOTIDES; HETEROZYGOTE; HUMANS; INFANT; MALE; METHYLTRANSFERASES; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THIOGUANINE; THIONUCLEOTIDES;

EID: 84874941681     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12066     Document Type: Article

References (53)

1. Hann I, Vora A, Richards S, Hill F, Gibson B, Lilleyman J, Kinsey S, Mitchell C, Eden OB. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. Leukemia 2000; 14: 356-363.
2. Hann IM, Stevens RF, Goldstone AH, Rees JKH, Wheatley K, Gray R, Burnett AK. Randomized comparison of DAT versus ADE as induction therapy in children and younger adults with acute myeloid leukaemia. Results of the Medical Research Council's 10th AML Trial (MRC AML 10). Blood 1997; 89: 2311-2318.
3. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662.
4. Balis FM Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukaemia: a joint Children's Cancer Group and Pediatric Oncology Branch study. Blood 1998; 92: 3569-3577.
5. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-154.
6. Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reactions of 6-mercaptopurine. Cancer Res 1974; 34: 738-746.
7. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006; 79 and 80: 153-170.
8. Hogarth LA, Redfern CPF, Teodoridis JM, Hall AG, Anderson H, Case MC, Coulthard SA. The effect of thiopurine drugs on DNA methylation in relation to TPMT expression. Biochem Pharmacol 2008; 76: 1024-1035.
9. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtman M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-1145.
10. Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, Strand D, Tanaka S, Galle PR, Bustelo XR, Neurath MF. Azathioprine suppresses Ezrin-Radixin-Moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006; 176: 640-651.
11. Bourgine J, Garat A, Allorge D, Crunelle-Thibaut A, Lo-Guidice JM, Colombel JF, Brolly F, Billaut-Laden I. Evidence for a functional genetic polymorphism of Rho-GTPase Rac1. Implication in azathioprine response? Pharmacogenet Genomics 2011; 21: 313-324.
12. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase deficient child with acute lymphoblastic leukaemia. J Pediatr 1991; 119: 985-989.
13. Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies. Med Pediatr Oncol 1997; 29: 252-255.
14. McBride KL, Gilchrist GS, Smithson WA, Weinshilboum RM, Szumlanski CL. Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukaemia and inherited thiopurine methyltransferase deficiency. J Pediatric Hematology Oncology 2000; 22: 441-445.
15. Lennard L, Lilleyman JS, Van Loon JA. Weinshilboum RM Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-229.
16. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui C-H, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
17. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenetic test whose time has come. J Clin Pathol 2010; 63: 288-295.
18. Relling MV, Gardner EE, Sandborn WJ, Pui C-H, Stein CM, Carrillo M, Evans WE, Klein TE. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89: 387-391.
19. Schaeffeler E, Fisher C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger UM, Schwab M. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-417.
20. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, Iven H, Schmeigelow K, Branum E, O'Brien J, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
21. Vora AJ, Mitchell CD, Lennard L, Eden TOB, Kinsey SE, Lilletman JS, Richards S. Toxicity and efficacy of thioguanine compared with mercaptopurine in childhood lymphoblastic leukaemia: results of the UK Medical Research Council Randomised Trial ALL97. Lancet 2006; 368: 1339-1348.
22. Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora AJ. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukaemia. Clin Pharmacol Ther 2006; 80: 375-383.
23. Mitchell CD, Richards SM, Lilleyman J, Vora A, Eden OB. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomised trial. Br J Haematol 2005; 129: 734-745.
24. Lennard L, Singleton HJ. High performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B 1994; 661: 25-33.
25. Lennard L, Singleton H. High performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992; 583: 83-90.
26. Lennard L, Chew TS, Lilleyman JS. Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol 2001; 52: 539-546.
27. Rostami-Hodjegan A, Lennard L, Lilleyman JS. The accumulation of mercaptopurine metabolites in age fractionated red blood cells. Br J Clin Pharmacol 1995; 40: 217-222.
28. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993; 68: 186-190.
29. Lancaster DL, Patel N, Lennard L, Lilleyman JS. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine numcleotide concentrations. Br J Clin Pharmacol 2001; 51: 531-539.
30. Brouwer C, De Abreu RA, Keizer-Garritsen JJ, Lambooy LHJ, Ament K, ter Reit PGJH, van Wering ER, Trijbels FJM, Veerman AJP, Hooherbrugge PM, Bokkerink JPM. Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects. Eur J Cancer 2005; 41: 613-623.
31. Fakoury M, Andreu-Gallien J, Mahr A, Medard Y, Azougagh S, Vilmer E, Jacqz-Aigrain E. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? J Clin Pharm Ther 2007; 32: 633-639.
32. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 7: 1897-1902.
33. Lindqvist M, Hindorf U, Almer S, Soderkvist P, Strom M, Hjortswang H, Peterson C. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1033-1037.
34. Gisbert JP, Gomollon F, Cara C, Luna M, Gonzalez-Lama Y, Pajares JM, Mate J, Guijarro LG. Thiopurine methyltransferase activity in Spain: a study of 14, 545 patients. Dig Dis Sci 2007; 52: 1262-1269.
35. de Boer NKH, van Bodegraven AA, de Graaf P, van der Hulst RWM, Zoetekouw L, van Kuilenburg ABP. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. Ther Drug Monit 2008; 30: 390-393.
36. McLeod HL, Krynetski EY, Williams JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995; 5: 281-286.
37. Serpe L, Calvo PL, Muntoni E, D'Antico S, Giaccone M, Avagnina A, Baldi M, Barbera B, Curti F, Pera A, Eandi M, Zara GP, Canaparo R. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics 2009; 10: 1753-1765.
38. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, Vinner E, Marez D, Lo Guidice J-M, Chevalier D, Brique S, Motte K, Colombel J-F, Turck D, Noel C, Flipo R-M, Pol A, Lhermitte M, Lafitte J-J, Libersa C, Broly F. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125: 879-887.
39. Booth RA, Ansari MT, Loit E, Tricco AC, Weeks L, Doucette S, Skidmore B, Sears M, Sy R, Karsh J. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011; 154: 814-823.
40. Yan L, Zhang S, Eiff B, Szumlanski CL, Powers M, O'Brien JF, Weinshilboum RM. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000; 68: 210-219.
41. Arenas M, Simpson G, Lewis CM, Shobwale-Bakre E-M, Escuredo E, Fairbanks LD, Duley JA, Ansari A, Sanderson JD, Marinaki AM. Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin Chem 2005; 51: 2371-2374.
42. Ford L, Kampanis P, Berg J. Thiopurine S-methyltransferase genotype-phenotype concordance: used as a quality assurance tool to help control the phenotype assay. Ann Clin Biochem 2009; 46: 152-154.
43. Nelson JA. Mechanisms of action of thiopurines used in the curative therapy for childhood leukaemias. Cancer Bull 1992; 44: 470-473.
44. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005; 15: 801-815.
45. Rutherford K, Daggett V. Four human thiopurine S-methyltansferase alleles severely affect protein structure and dynamics. J Mol Biol 2008; 379: 803-814.
46. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25: 1629-1638.
47. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of 6-mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance. Br J Cancer 1995; 72: 1004-1006.
48. Lau RCW, Matsui D, Greenberg M, Koren G. Electronic measurement of compliance with mercaptopurine in pediatric pateints with acute lymphoblastic leukaemia. Med Pediatr Oncol 1998; 30: 85-90.
49. Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, Hanby CL, Leisenring W, Yasui Y, Kornegay NM, Mascarenhas L, Ritchey AK, Casillas JN, Dickens DS, Meza J, Carroll WL, Relling MV, Wong FL. Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 2012; 30: 2094-2101.
50. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004; 75: 274-281.
51. Gardiner S, Gearry RB, Burt MJ, Ding SJ, Barclay ML. Severe hepatoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur J Gastroenterol Hepatol 2008; 20: 1238-1242.
52. de Beaumais TA, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, Jacqz-Aigrain E. Determinants of mercaptopurine toxicity in paediatric acute leukaemia maintenance therapy. Br J Clin Pharmacol 2011; 71: 575-584.
53. Schmeigelow K, Pulczynska M. Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia. Br J Cancer 1990; 61: 767-772.